Literature DB >> 12160805

Factors affecting visual outcomes after small-incision phacoemulsification in diabetic patients.

Mamta D Somaiya1, Jason D Burns, Roni Mintz, Robert E Warren, Tatsuo Uchida, Bernard F Godley.   

Abstract

PURPOSE: To examine the factors affecting visual outcome after phacoemulsification and evaluate the use of preoperative visual potential in assessing the visual prognosis in diabetic patients.
SETTING: Department of Ophthalmology, University of Texas Medical Branch, Galveston, Texas, USA.
METHODS: In a retrospective chart review of 1345 consecutive patients who had uneventful small-incision phacoemulsification, operated eyes from 106 diabetic and 55 nondiabetic control patients were selected. Data on demographics, level of retinopathy, perioperative glycosylated hemoglobin (HbA(Ic)), surgical duration, preoperative best corrected visual acuity (BCVA), and visual potential were collected.
RESULTS: The age, sex, preoperative BCVA, and visual potential in the diabetic and control eyes were comparable. Throughout the postoperative period, BCVA was worse of the diabetic group. At 1 year, BCVA was 20/40 in 82.1% of the diabetic group and 94.7% of the control group (P =.01). The most important factors affecting postoperative BCVA included coexisting diabetes and preoperative level of retinopathy. No correlation was found between perioperative and postoperative BCVA. Diabetic patients were less likely than control patients to achieve a BCVA better than or equal to the preoperative visual potential at 4 years (hazard ratio 0.6; 95% confidence interval, 0.4-0.9; P =.011). Patients with nonproliferative diabetic retinopathy were nearly 5 times less likely (P =.023) and patients with proliferative diabetic retinopathy 30 times less likely (P <.0001) to achieve a postoperative BCVA of 20/40 than diabetic patients without retinopathy.
CONCLUSIONS: Although uneventful small-incision phacoemulsification improved visual acuity in diabetic patients, this group had an overall worse visual outcome than nondiabetic patients. The most important predictors of visual outcome were coexisting diabetes and the extent of preoperative retinopathy. Methods used to assess preoperative visual potential provided a reasonable estimate of postoperative BCVA in diabetic patients. Given the inverse association between the level of retinopathy and visual outcome, it may be better to perform cataract extraction in diabetic patients during earlier stages of retinopathy.

Entities:  

Mesh:

Year:  2002        PMID: 12160805     DOI: 10.1016/s0886-3350(02)01319-6

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

1.  Severe adverse events after cataract surgery among medicare beneficiaries.

Authors:  Joshua D Stein; Daniel S Grossman; Kevin M Mundy; Alan Sugar; Frank A Sloan
Journal:  Ophthalmology       Date:  2011-06-02       Impact factor: 12.079

2.  The Auckland Cataract Study: 2 year postoperative assessment of aspects of clinical, visual, corneal topographic and satisfaction outcomes.

Authors:  A M Thompson; N Sachdev; T Wong; A F Riley; C N Grupcheva; C N McGhee
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

3.  Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema.

Authors:  Carl W Baker; Talat Almukhtar; Neil M Bressler; Adam R Glassman; Sandeep Grover; Stephen J Kim; Timothy J Murtha; Michael E Rauser; Cynthia Stockdale
Journal:  JAMA Ophthalmol       Date:  2013-07       Impact factor: 7.389

4.  Combined intravitreal bevacizumab with phacoemulsification in visually significant cataract and visually significant exudative maculopathy.

Authors:  Ahmad Mansour; Ziad F Bashshur; Tarek A Sibai; Abla Mehio-Sibai; Rola N Hamam
Journal:  Oman J Ophthalmol       Date:  2011-01

5.  Cataract and diabetic retinopathy.

Authors:  James Rice
Journal:  Community Eye Health       Date:  2011-09

6.  The combination of phacoemulsification surgery and intravitreal triamcinolone injection in patients with cataract and diabetic macular edema.

Authors:  Ozlen Rodop Ozgur; Yelda Ozkurt; Zeynep Kulekci; Tufan Evciman
Journal:  Saudi J Ophthalmol       Date:  2015-10-30

7.  Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema.

Authors:  Claudio Furino; Francesco Boscia; Alfredo Niro; Ermete Giancipoli; Maria Oliva Grassi; Giuseppe D'amico Ricci; Francesco Blasetti; Michele Reibaldi; Giovanni Alessio
Journal:  J Ophthalmol       Date:  2017-08-13       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.